drugset / Trial / NCT04499352
A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The objective of this trial is to assess anti-tumour activity of BI 754091 as monotherapy and of BI 754091 in combination with BI 836880 in patients with unresectable or metastatic squamous cell carcinoma of the anal canal who progressed on or after chemotherapy.
Timeline
- Start
- 2020-09-14
- Primary completion
- 2020-10-19
- Completion
- 2020-10-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BI 836880 | Protein / enzyme biologic | — | — |
| Subject | Ezabenlimab | Monoclonal antibody | — | — |